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INTRODUCTION
Allergic rhinitis (AR) is a chronic upper airway disease of in-
creasing prevalence and remains an important healthcare 
problem. The condition can have a major detrimental impact 
on quality-of-life and social productivity.1 Clinical practice 
guidelines for the management of AR recommend clear goals, 
including the prevention of allergy, reduction in allergen expo-
sure, and effective pharmacological treatment.2
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Purpose: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine 
combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Subjects exhibiting moderate to severe 
allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 µg cicle-
sonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by re-
flective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms 
severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). Results: Significant improvements in rTNSS, PANS, and RQLQ in the 
ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny 
nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from 
baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Cicle-
sonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were 
well tolerated alone and  in combination. Conclusions: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation 
stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not 
give further clinical benefit over monotherapy.
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Based on Allergic Rhinitis and its Impact on Asthma (ARIA) 
guidelines revised in 2010 for pharmacological treatment, in-
tranasal glucocorticosteroids (INCSs) are strongly recommend-
ed for the treatment of adults with AR on the basis of reliable 
evidence. However, only conditional recommendations exist 
for its use in preference to oral H1-antihistamines (OAHs) for 
both seasonal AR (SAR) and perennial AR (PAR) on the basis of 
low- to moderate-quality evidence. ARIA guidelines also em-
phasize the need to respect patient preferences.2 ARIA guide-
lines do not recommend a combination of INCSs and OAHs for 
the treatment of AR, although such combinations are often pre-
scribed in clinical practice.
Ciclesonide is a corticosteroid agent normally administered 
as an aqueous nasal spray and has been validated as providing 
therapeutic relief for AR.3,4 Ciclesonide is a prodrug that is enzy-
matically hydrolyzed to its pharmacologically active metabo-
lite, C21-desisobutyryl-CIC, with an associated 100-fold higher 
corticosteroid receptor-binding affinity than that of the inactive 
parent compound.5,6 Ciclesonide was approved by the U.S. 
Food and Drug Administration (U.S. FDA) for the treatment of 
SAR and PAR in 2006.7
Although a series of studies comparing the efficacy of intrana-
sal spray to that of OAH have shown modest benefits for INCS, 
the quality of evidence to date has not been strong enough to 
justify a definitive recommendation of INCSs over OAHs ac-
cording to ARIA guidelines.8 In the current study, we thus aimed 
to comparatively assess the efficacy and safety of ciclesonide na-
sal spray monotherapy to that of levocetirizine monotherapy as 
well as combination treatment in patients with AR.
MATERIALS AND METHODS
Patients
We recruited subjects aged≥18 years, who had exhibited 
signs and symptoms of AR for longer than 1 year. In accordance 
with ARIA guidelines, only subjects with moderate to severe 
SAR or PAR were included. All subjects tested were positive for 
skin allergy tests (skin prick test) or serological allergy tests, in-
cluding for multiple allergen simultaneous tests (MAST), to 1 or 
more specified allergens less than 1 year prior to screening. The 
administration of drugs for AR before the screening visit and 
during the wash-out period of 1 to 3 weeks was not permitted. 
Subjects were required to write diaries recording self-assess-
ments of their AR symptoms. Subjects were also required to 
have a mean reflective total nasal symptom score (rTNSS) ≥6 
for 4 days or longer during the week prior to the baseline visit or 
a mean rTNSS ≥6 for 7 days prior to the baseline visit.
Subjects with active asthma requiring treatment with inhaled 
or systemic corticosteroids and/or routine use of beta-agonists 
or any other medications were excluded. Additional exclusion 
criteria were: nasal pathologies, including nasal polyps or bron-
chial anomalies; chronic obstructive pulmonary disease; clini-
cally significant renal disease (serum creatinine levels greater 
than 1.5 mg/dL for men or 1.4 mg/dL for women), liver disease 
(ALT or AST >[3X UNL]) within 2 months before the screening 
visit; intranasal biopsy revealing ulcers, trauma, surgery, atro-
phic rhinitis or drug-derived rhinitis within 2 months before 
screening; respiratory infections within 2 weeks before or dur-
ing screening; usage of systemic steroids within 2 months of 
screening or local steroids (hydrocortisone >1%) within 4 
weeks of screening or antibiotic treatment within 2 weeks of 
screening; a possibility of receiving medications like systemic 
corticosteroids or high-dose steroids, beta-agonists or other in-
vestigational drugs that were not permitted in the protocol dur-
ing the study period; known or suspected hypersensitivity to 
ciclesonide or hydroxyzine; and genetic disorders such as ga-
lactose intolerance, Lapp lactase deficiency or glucose-galac-
tose malabsorption.
Study design and treatment
This was an open-label, 3-arm, parallel-group randomized 
study (NCT01430260). Subjects were randomly assigned to the 
following 4 groups: (1) the study group receiving 200 µg cicle-
sonide (Omnaris®, Nycomed GmbH, Singen, Germany) nasal 
spray (cidesonide group, n=88) and the control groups receiv-
ing 5 mg levocetirizine (Xyzal®, UCB Farchim SA, Bulle, Swit-
zerland) (levocetrizine group, n=89) or 200 µg ciclesonide na-
sal spray +5 mg levocetirizine at a ratio of 1:1:1 (combination 
treatment group, n=83). Randomization was achieved through 
the application of a block randomization method at each study 
center (2 block sizes were combined for randomization), with 
random numbers generated using the SAS® Software Package. 
Subjects who were eligible for participation in the study re-
ceived a randomly-generated number (4 digits) in accordance 
with the study enrollment order. The study investigators pre-
scribed the investigational products in accordance with the 
randomization, and study pharmacists distributed the investi-
gational products using identical randomization methods.
In the study group, 200 µg ciclesonide nasal spray was admin-
istered once daily in the mornings. The control groups received 
either 5 mg levocetirizine once daily in the morning, or 200 µg 
ciclesonide nasal spray in combination with 5 mg levocetirizine 
taken orally once daily in the morning. Subject dropout rates 
were determined by the investigators via interviews with sub-
jects and via the investigators’ judgment upon each visit. The 
subjects were required to visit the trial site a total of 3 times dur-
ing the 3-5 weeks of the study.
Efficacy assessments
The primary endpoint was the change from baseline in the 
mean value of patient-reported rTNSS (morning and evening) 
averaged over the 2-week treatment period. Patient diaries were 
used to record rTNSS by evaluating symptom severity over the 
12 hours prior to the recording of the score. The rTNSS was cal-
Kim et al.
Allergy Asthma Immunol Res. 2015 March;7(2):158-166. http://dx.doi.org/10.4168/aair.2015.7.2.158160  http://e-aair.org
Volume 7, Number 2, March 2015
culated as the sum of 4 nasal symptoms: rhinorrhea, nasal itch-
ing, nasal congestion, and sneezing, each of which was rated on 
a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms 
causing significant discomfort that interfered with daily activi-
ties) for the full analysis set (FAS) population.
Major secondary endpoints were efficacy parameters involv-
ing changes in reflective total ocular symptom score (rTOSS), 
each item of the rTNSS, physician-assessed overall nasal signs 
and symptoms severity (PANS) and the rhinoconjunctivitis 
quality-of-life questionnaire (RQLQ) with standardized activi-
ties, compared between values at baseline and over the 2-week 
treatment period. The rTOSS was calculated as the sum of 3 oc-
ular symptoms: itchy eyes, red eyes, and watery eyes, each rat-
ed on a scale of 0 (no signs/symptoms evident) to 3 (signs/
symptoms causing significant discomfort that interfered with 
daily activities). PANS values were obtained from the investiga-
tors’ assessments of nasal signs (discoloration, swelling, dis-
charge and postnasal drip) and symptoms (rhinorrhea, itching, 
nasal congestion and sneezing). RQLQ was obtained via patient 
self-assessment of the 28 listed items.
Safety assessment
The frequency and percentage of adverse events (AEs), as well 
as serious AEs and those that caused dropouts were analyzed 
for correlations with treatment types, body organs affected, and 
preferred terms. Vital signs were analyzed using descriptive sta-
tistics for differences in data obtained at the baseline and termi-
nation visits among the treatment groups. A comparative physi-
cal examination assessment was conducted using data from the 
baseline and the termination visits, which was summarized for 
each subject. In particular, subjects who were assessed to be 
normal at the baseline visit, but abnormal at the termination 
visit were carefully reviewed for fulfillment of AE criteria.
Statistical methods
The FAS population was used for analysis of all efficacy end-
points. Subjects who did not receive the investigational prod-
ucts after randomization or did not undergo scheduled efficacy 
assessments at baseline or thereafter were excluded from fur-
ther analysis. The Safety Analysis Set consisted of all subjects 
who received the investigational products at least once after 
study enrollment.
For a comparative assessment of the efficacy of: 1) 200 µg 
ciclesonide nasal spray administered alone once daily, 2) levo-
cetirizine administered alone at a dose of 5 mg once daily, and 
3) ciclesonide nasal spray in combination with levocetirizine in 
patients with AR, a number of statistical methods were em-
ployed.
The null and alternative hypotheses (H0 and H1, respectively) 
for this study aimed to assess statistical significance for mean of 
the population for change from baseline in rTNSS. The letter μ 
was used to denote the mean value of a given population. The 
study’s hypotheses were as follows:
H0:  μ ciclesonide=μ levocetirizine=μ ciclesonide+levocetirizine
H1: The 3 population means are not equal.
In order to assess these hypotheses, statistical analysis was 
undertaken in 2 parts. First, Analysis of Variance (ANOVA) was 
conducted to compare the change between the 3 groups in 
mean rTNSS in the mornings and evenings before and after 
treatment. Second, rejection of the null hypothesis was fol-
lowed up with multiple comparison analyses using Fisher’s 
Least Significant Difference (LSD). 
The same methods were employed to compare the secondary 
efficacy endpoints of changes in rTOSS, each item of the rTNSS, 
PANS, and RQLQ. Exploratory analysis for the correlation of 
rTNSS and PANS was conducted using Pearson’s correlation 
analysis. 
A detailed description of the statistical method was provided 
in the statistical analysis plan. The criterion for statistical signif-
icance was P<0.05. Continuous data outputs are presented us-
ing descriptive statistics (subject number, mean, standard devi-
ation, minimum, median, maximum, and quartiles), while cat-
egorical data are presented using frequency and percentage. 
Where applicable, a 95% confidence interval is presented.
IRB review
The study protocol, written informed consent form, and all 
relevant documents were reviewed and approved by the Insti-
tutional Review Board (IRB) of each study center.
RESULTS
Patient disposition and baseline characteristics
A total of 349 patients were screened for study participation. 
Of these 349 patients, 260 (74.5%) were randomized to the study 
group (ciclesonide group, n=88) and the control groups receiv-
ing, levocetirizine (levocetrizine group, n=89) or ciclesonide 
combined with levocetirizine (combination treatment group, 
n=83) (Fig. 1).
Two subjects were excluded from efficacy analysis but includ-
ed for safety analysis. Of these 2 patients, one from the combina-
tion treatment group dropped out of the study due to absence in 
the follow-up period; the other from the levocetirizine group 
was unable to locate their patient diary. Patient diaries were the 
source data that carried all relevant information; if there was no 
patient diary, then there was no efficacy data either.
Another patient from the levocetirizine group experienced a 
randomization error and was inadvertently dosed with cicle-
sonide. This subject’s data were analyzed as belonging to the le-
vocetirizine group when assessing efficacy, but as the cicle-
sonide group when assessing safety.
A total of 13 study sites were used, and the number of study 
patients ranged from 12 to 32 per site.
Demographic and other baseline characteristics were similar 
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Enrolled,
n=349
Screening failure, 
n=89
Randomized,
n=260
Ciclesonide 
+Levocetirizine,
n=83
Levocetirizine, 
n=89
Ciclesonide, 
n=88
Drop – out
n=0
Drop – out
n=0
Completed, 
n=88
Completed, 
n=89
Completed, 
n=82
Excluded
n=1
Full analysis set (n=258)
Ciclesonide, n=88
Levocetirizine, n=88
Ciclesonide + Levocetirizine, n=82
Drop – out
n=1
Fig. 1. Study flow and subject disposition. A total of 258 subjects aged ≥18 years successfully completed the study. Subjects were randomly assigned to treatment 
groups receiving 200 µg ciclesonide nasal spray, 5 mg oral levocetirizine, or a combination of both.
Table 1. Patient Characteristics (FAS)
Ciclesonide Levocetirizine Ciclesonide+ Levocetirizine Total Statistics
P valueNumber n=88 n=88 n=82 n=258
Demographics 
   Age (years), Mean [SD] 32.9 [11.3] 32.9 [10.2] 29.8 [9.6] 31.9 [10.5] 0.0933*
   Sex, M/F (%) 43.2/56.8 54.5/45.5 46.3/53.7 48.1/51.9 0.2984‡
   Height (cm), Mean [SD] 165.8 [7.9] 167.7 [8.8] 167.1 [7.7] 166.8 [8.2] 0.2783*
   Weight (kg), Mean [SD] 61.8 [11.8] 64.2 [11.8] 63.3 [11.9] 63.1 [11.8] 0.4073*
   BMI (kg/m2), Mean [SD] 22.4 [3.0] 22.7 [3.1] 22.5 [3.2] 22.5 [3.1] 0.7605*
Duration of allergic rhinitis (years) Mean [SD] 10.2 [6.9] 9.8 [6.3] 9.5 [6.2] 9.9 [6.4] 0.7834*
Classification of allergic rhinitis
   Seasonal, n (%) 28 (31.8) 21 (23.9) 24 (29.3) 73 (28.3) 0.4905†
   Perennial, n (%) 59 (67.1) 67 (76.1) 58 (70.7) 184 (71.3)
   Both, n (%) 1 (1.1) 0 0 1 (0.4)
ARIA Classification (Moderate to Severe), n (%) 88 (100.0) 88 (100.0) 82 (100.0) 258 (100.0)
Baseline individual nasal symptoms
   Mean rTNSS [SD] 7.5 [1.5] 7.3 [1.2] 7.6 [1.4] 7.5 [1.4] 0.5516*
   Mean rTOSS [SD] 2.9 [2.1] 2.4 [1.8] 2.9 [1.8] 2.7 [1.9] 0.1493*
   Mean PANS [SD] 2.0 [0.5] 1.9 [0.5] 1.9 [0.5] 1.9 [0.5] 0.8989*
   Mean RQLQ [SD] 4.1 [0.9] 3.8 [0.9] 4.1 [1.1] 4.0 [1.0] 0.0945*
*ANOVA; †Fisher’s exact test; ‡Chi-square test.
FAS, full analysis set; SD, standard deviation; BMI, body-mass Index; ARIA, allergic rhinitis and its impact on asthma; rTNSS, reflective total nasal symptom score; 
rTOSS, reflective total ocular symptom score; PANS, physician-assessed overall nasal signs and symptoms severit; RQLQ, rhinoconjunctivitis quality-of-life question-
naires.
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in all treatment groups, while the distribution of seasonal and 
perennial AR was at a 3:7 ratio. Mean baseline rTNSS, rTOSS, 
PANS, and RQLQ scores were similar across the 3 treatment 
groups (Table 1).
Efficacy
The efficacy analysis was performed using the FAS with a total 
of 258 patients. After 2 weeks of treatment, the ciclesonide 
group showed significantly improved rTNSS, PANS, and RQLQ 
in comparison to the levocetirizine group (Fig. 2). A similar de-
gree of improvement was seen in the combination treatment 
group (Fig. 2). Values of rTOSS scores improved from the base-
line in the ciclesonide group, but no superiority over the levo-
cetirizine group was observed. For all efficacy parameters, levo-
cetirizine did not provide any additional benefit when given in 
combination with ciclesonide, compared to ciclesonide alone. 
In comparison to the change in mean individual symptoms, 
the mean rTNSS for rhinorrhea, itching, and nasal congestion 
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Parameters
   (Change)
Ciclesonide
(n=88)
Levocetirizine
(n=88)
Ciclesonide+Levocetirizine
(n=82)
P value
rTNSS Mean [SD] -3.9 [2.2] -3.0 [2.1] 3.9 [2.6] 0.0141
rTOSS Mean [SD] -1.4 [1.6] -0.9 [1.4] -1.3 [1.6] 0.1060
PANS Mean [SD] -1.1 [0.7] -0.8 [0.6] -1.1 [0.6] 0.0002
RQLQ Mean [SD] -1.4 [1.0] -1.1 [1.0] -1.6 [1.2] 0.0101
Fig. 2. Changes in efficacy parameters. Analysis of symptom severity was conducted using reflective total nasal symptom score (rTNSS) values recorded in patient 
diaries and averaged over the 2-week period. The rTNSS was calculated as the sum of four nasal symptoms: rhinorrhea, nasal itching, nasal congestion, and sneez-
ing, each of which was rated on a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms causing significant discomfort that interfered with daily activities) 
for the full analysis set (FAS) population. The Reflective total ocular symptom score (rTOSS) was calculated as the sum of three ocular symptoms: itchy eyes, red 
eyes, and watery eyes, each rated on a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms causing significant discomfort that interfered with daily activi-
ties). physician-assessed overall nasal signs and symptoms severity (PANS) values were obtained from the investigators assessments of nasal signs (discoloration, 
swelling, discharge, and postnasal drip) and symptoms (rhinorrhea, itching, nasal congestion, and sneezing). Rhinoconjunctivitis quality-of-life questionnaires (RQLQ) 
was obtained via patient self-assessment of the 28 listed items. SD, standard deviation.
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were decreased significantly in the ciclesonide group compared 
to the levocetirizine group (P=0.0388, P=0.0429, and P=0.0202 
respectively). Differences in the sneezing score were not ob-
served as a result of any of the treatments (P=0.4014, Fig. 3).
Subgroup analysis of SAR and PAR revealed a greater im-
provement in rTNSS in the ciclesonide and combination treat-
ment groups than in the levocetirizine group for both types. 
However, decreases in the mean rTNSS values varied with AR 
Table 2. Subgroup analysis by allergic rhinitis classification–change in rTNSS before and after treatment (FAS)
Classification                    Treatment
Mean P value*
(Within Treatment Groups)
P value†
(Between Treatment Groups)Baseline End of study Change
SAR Ciclesonide (n=28)‡ 7.4 4.0 -3.4 <.0001 0.1834
Levocetirizine (n=21) 7.8 5.1 -2.7 <.0001
Ciclesonide‡ Levocetirizine (n=24) 7.7 3.7 -4.0 <.0001
PAR Ciclesonide (n=59)‡ 7.6 3.5 -4.1 <.0001 0.0423
Levocetirizine (n=67) 7.2 4.1 -3.1 <.0001
Ciclesonide‡ Levocetirizine (n=58) 7.5 3.6 -3.9 <.0001
*P value by Paired t test; †P value by ANOVA; ‡Data entry for one subject failed to clarify whether the subject had SAR or PAR, so they were excluded from this analysis.
FAS, full analysis set; rTNSS, reflective total nasal symptom score; SAR, seasonal allergic rhinitis; PAR, perennial allergic rhinitis.
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Fig. 3. Changes in efficacy parameters. Analysis of symptom severity was conducted using rTNSS (reflective total nasal symptom score) values recorded in patient 
diaries and averaged over the 2-week period. The rTNSS was calculated as the sum of four nasal symptoms: rhinorrhea, nasal itching, nasal congestion, and sneez-
ing, each of which was rated on a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms causing significant discomfort that interfered with daily activities) 
for the full analysis set (FAS) population. The P  values shown in the figure measure statistical significance between C (ciclesonide) vs L (levocitirizine) vs C+L (combi-
nation treatment) groups at P<0.05 through ANOVA. The P value for rhinorrhea was 0.0388, for itching 0.0429, for nasal congestion 0.0202, and for sneezing 0.4014. 
If a P value indicated statistical significance at P<0.05 within a scoring system, additional comparative analyses were performed in order to clarify which groups 
were responsible for the significance. Significant comparisons at the 0.05 level are indicated by asterisks (*) through multiple comparison analysis by Fisher’s Least 
Significance Difference (LSD). Whiskers to the bars indicate SEM.
types (Table 2).
PANS was well correlated with rTNSS for baseline and termi-
nation visits and the percent change from baseline over 2 weeks 
(Fig. 4).
Safety
The durations of drug exposure were 15.9, 16.1, and 16.0 days 
for the ciclesonide, levocetirizine, and combination treatment 
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groups, respectively. Mean drug compliance for the ciclesonide, 
levocetirizine, and combination treatment groups were 97.7%, 
91.7%, and 93.4%, respectively. Drug compliance was relatively 
higher for ciclesonide than for levocetirizine (P<0.0001, data 
not shown).
Safety analysis was performed on 260 subjects (89 in the cicle-
sonide group, 88 in the levocetirizine group, and 83 in the com-
bination treatment group). The overall incidence of treatment-
emergent AEs (TEAEs) was low and comparable between the 
treatment groups. A total of 32 (12.3%) patients reported 45 
TEAEs with 11 (12.4%) patients in the ciclesonide group, 12 
(13.6%) patients in the levocetirizine group, and 9 (10.8%) pa-
tients in the combination treatment group. Four nasal AEs, 
which could not be ruled out as TEAEs, were reported in the 
ciclesonide group (1 nasal pain), the levocetirizine group (1 ep-
istaxis, 1 dry nose), and the combination treatment group (1 
dry nose). No serious AEs were reported in any treatment group 
for the duration of the study (Table 3).
DISCUSSION
The efficacy and safety of ciclesonide intranasal spray for 2-52 
weeks has previously been evaluated in 4 Phase III, random-
ized, placebo-controlled trials in adults and children with SAR 
Fig. 4. Correlation analysis between rTNSS and PANS. Exploratory analysis for the correlation of rTNSS and PANS was conducted using Pearson’s correlation analysis.
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Change (Δ) 0.4176 <0.0001
Table 3. Adverse drug reactions, of which a causal relationship with treatment could not be ruled out (Safety Analysis Set)
Ciclesonide Levocetirizine Ciclesonide+ Levocetirizine Total
(n=89) (n=88) (n=83) (n=260)
Patients with related AEs 1 (1.1%) 6 (6.8%) 5 (6.0%) 12 (4.6%)
Total related AEs 1 8 6 15
Dry mouth 0 2 (2.3%) 1 (1.2%) 3 (1.2%)
Sleepiness 0 2 (2.3%) 1 (1.2%) 3 (1.2%)
Dizziness 0 1 (1.1%) 1 (1.2%) 2 (0.8%)
Dry nose 0 1 (1.1%) 1 (1.2%) 2 (0.8%)
Upper abdominal pain 0 0 1 (1.2%) 1 (0.4%)
Headache 0 1 (1.1%) 0 1 (0.4%)
Nasal pain 1 (1.1%) 0 0 1 (0.4%)
Epistaxis 0 1 (1.1%) 0 1 (0.4%)
AE, adverse event.
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and PAR.7-10 Here, we report the results of our Phase IV open-la-
bel randomized study evaluating the efficacy and safety of intra-
nasal ciclesonide monotherapy in comparison to oral levocetiri-
zine monotherapy and levocetirizine in combination with cicle-
sonide. Ciclesonide monotherapy caused statistically significant 
improvements in rTNSS, PANS, and RQLQ over levocetirizine 
monotherapy. Significant improvements were also seen in pa-
tients who had nasal symptoms, including runny nose, itchy 
nose, and congestion. Ciclesonide combined with levocetirizine 
treatment also resulted in better treatment results over levoceti-
rizine monotherapy as assessed by rTNSS, PANS and RQLQ, but 
no additional benefits were observed as a result of the addition 
of the OAH. TEAEs were observed with low frequency and not 
significantly different among the 3 study groups.
This is the first randomized study conducted with a large pop-
ulation of moderate to severe AR patients in order to demon-
strate the superior efficacy and comparable safety of ciclesonide 
over levocetirizine. Although ARIA guidelines recommend INC-
Ss over OAHs for both adult SAR and PAR, it has remained a 
conditional recommendation based on low-quality evidence for 
SAR and evidence of moderate quality for PAR.2 The existence of 
conditional ARIA recommendations underlines the need for 
better clinical decision aids based on high-quality evidence.
The GRADE approach summarizes randomized trials in terms 
of their quality of evidence, with increasing quality associated 
with strong effects, dose-response relationships, and minimal 
confounding factors. It also penalizes study designs with inher-
ent risks, inconsistencies, indirectness, imprecision, and publi-
cation bias.2 Our study design involved a randomized trial with 
substantial sample sizes in all 3 groups, although it was open-la-
bel. This study can be classified as having a moderate quality ac-
cording to the GRADE approach. Benninger et al.11 conducted a 
comprehensive meta-analysis of 54 randomized trials involving 
more than 14,000 patients and reported that INCSs produce the 
greatest improvements over other pharmacological treatments, 
including OAHs for SAR. In addition, it is concluded that INCSs 
are effective for the treatment of PAR, although OAHs may be 
equally effective for some patients.12 Nevertheless, current ARIA 
guidelines conditionally recommend INCSs versus OAHs be-
cause INCS treatment has low- to moderate-quality evidence. 
Our study fulfills the definition of moderate quality for AR stud-
ies, including SAR and PAR. In our study, the addition of levoce-
tirizine to ciclesonide did not result in further benefits over 
ciclesonide monotherapy, although the combination treatment 
did demonstrate an improvement of AR parameters over those 
of levocetirizine alone. To date, evidence has not been provided 
to support the contention that a combination of INCSs and 
OAHs is better than INCS treatment alone.12
Chung et al.13 reported more than 60% of patients with SAR 
showed persistent symptoms, while 33% of patients with PAR 
had intermittent symptoms, suggesting a lack of association be-
tween the SAR/PAR/PAR+SAR classification and the ARIA clas-
sification for the Korean population, as discussed in previous 
reports.14,15 The current study has shown that ciclesonide treat-
ment provides greater improvement of nasal symptoms over le-
vocetirizine treatment and that rTNSS and PANS scores at base-
line and termination visits were very closely correlated, as were 
changes in rTNSS and PANS scores after treatment. Moreover, 
rTNSS is currently the most preferred tool for measuring the 
control of AR nasal symptoms in subject self-assessment re-
ports during clinical trials.11 These reports focused on patients’ 
subjective symptoms. Our results also support the notion that 
PANS is an effective tool to support or replace rTNSS in clinical 
trials and medical practice, especially for patients with poor 
compliance in self-assessment. Further studies are required to 
validate this notion.
We acknowledge limitations to our study. First, the treatment 
protocol involved a relatively short duration of 14 days, espe-
cially for PAR. Some studies with INCSs have included treat-
ment durations of up to 5-6 weeks, revealing important data, 
such as reductions in treatment effects that arise after an ex-
tended period of time. However, these studies were conducted 
on SAR patients, with seasonal pollen counts also decreasing 
over the duration of the study. Second, this study has used sev-
eral tools to measure disease severity, including rTNSS, rTOSS, 
PANS, and RQLQ, rather than tools to show treatment effect. Al-
though most clinical studies evaluating pharmacological treat-
ment effects in AR have utilized disease severity assessment 
tools, recent review articles recommend the use of more com-
prehensive assessment tools, such as Control of Allergic Rhini-
tis and Asthma Test (CARAT), Radioallergosorbent Test (RAST), 
Allergic Rhinitis Control Test (ARCT), and State of the Impact of 
Allergic Rhinitis on Asthma Control (SACRA). This is because 
treatment effects are more accurately assessed using tools for 
disease control rather than those designed to assess disease se-
verity.16,17 However, we believe that the multiple disease severi-
ty tools we employed are sufficiently balanced to objectively re-
flect the effects of treatment. In addition, rTNSS still remains 
one of the standard parameters requested by the FDA.
In conclusion, we report that INCS ciclesonide spray was more 
effective in reducing the nasal symptoms of AR than the OAH 
levocetirizine for the treatment of moderate to severe AR in 
adult subjects. A combination of levocetirizine and ciclesonide 
did not provide additional benefits to ciclesonide monotherapy. 
Additional studies of longer duration may provide further in-
sights into the long-term effects of treatment.
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